Benin
Tuberculosis profile
| High HIV burden |
Population  2013 10 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.3 (0.76–1.7) 12 (7.3–17)
Mortality (HIV+TB only) 0.35 (0.27–0.44) 3.4 (2.6–4.3)
Prevalence  (includes HIV+TB) 11 (5.8–17) 105 (56–168)
Incidence  (includes HIV+TB) 7.2 (6.4–8) 70 (62–78)
Incidence (HIV+TB only) 1.1 (0.99–1.3) 11 (9.6–12)
Case detection, all forms (%) 54 (48–61)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.5 (0.1–2) 13 (8.2–20)
MDR-TB cases among notified pulmonary
TB cases
17 (3–68) 32 (20–47)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 3 129   150
Pulmonary, clinically diagnosed 294    
Extrapulmonary 293    
       
Total new and relapse 3 866    
Previously treated, excluding relapses 91    
Total cases notified 3 957    
Among 3 129 new cases:
48 (2%) cases aged under 15 years; male:female ratio: 1.9
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 59 (2%) 203 (84%) 262
Laboratory-confirmed RR-/MDR-TB cases     14
Patients started on MDR-TB treatment     6
TB/HIV 2013 Number (%)
TB patients with known HIV status 3 730 (94)
HIV-positive TB patients 587 (16)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 90
Previously treated cases registered in 2012 86
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 50
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0.5
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 1.7
% Funded domestically 9%
% Funded internationally 91%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-19 Data: www.who.int/tb/data